Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses future methods of treating patients with thyroid cancer.

Individual subsets of thyroid cancer are beginning to be discovered as indolent disease, Randolph explains. These include microcarcinomas, NIFTP lesions, and smaller tumors without nodal disease. These clinical parameters will be made more robust via a better understanding of the genomic makeup of these lesions.

Less aggressive treatment can then be given to patients who have a disease that is biologically understood to be a more indolent course, Randolph adds.

Videos

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future methods of treating patients with thyroid cancer.

Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, discusses how the role of surgery has evolved for patients with thyroid cancer.

Thyroid cancer management is is moving towards a more multidisciplinary approach, Randolph explains.

It is important to note that specialists such as endocrinologists have a role in tumor surveillance, for example, and there is an increasing number of endocrinologists with oncologic experience. Oncologists are taking a more active role in the multidisciplinary treatment of patients with advanced disease, he adds.

Gregory W. Randolph, MD

Articles

Dr. Randolph on Future Treatment Approaches in Thyroid Cancer

Dr. Randolph on Evolving Role of Surgery for Patients With Thyroid Cancer